Integrated analysis finds vulnerabilities to target in a high-risk pediatric tumor

August 23, 2018, St. Jude Children's Research Hospital
Elizabeth Stewart, M.D., and Hong Wang, Ph.D. of St. Jude Children's Research Hospital. Credit: St. Jude Children's Research Hospital

St. Jude Children's Research Hospital investigators have completed the most comprehensive analysis yet of a common pediatric solid tumor, identifying weaknesses to target and a promising precision medicine that is now in clinical trials. The findings appear today in the journal Cancer Cell.

The research, part of the St. Jude Children's Research Hospital—Washington University Pediatric Cancer Genome Project, focused on the muscle and soft tissue rhabdomyosarcoma. The tumor occurs in about 350 children and adolescents nationwide each year. Cure rates are 75 percent for patients whose tumors have not spread, but long-term survival is 30 percent or less for those with metastatic disease or those whose tumor returns. For these high-risk patients, overall survival has not improved significantly in 15 years.

"Recent advances in technology allowed us to extensively profile rhabdomyosarcoma to better understand its cellular origins as well as identify and prioritize vulnerabilities that extend beyond just the somatic (tumor) mutations," said Elizabeth Stewart, M.D., an assistant member of the St. Jude Department of Oncology. Stewart, Hong Wang, Ph.D., and Xiang Chen, Ph.D., of St. Jude, and Justina McEvoy, Ph.D., formerly of St. Jude, are co-first authors.

Researchers identified several signaling pathways that are disrupted in tumor cells. AZD1775, or adavosertib, inhibits an enzyme in one of the newly identified disrupted pathways. Extensive preclinical testing followed, results of which prompted the Children's Oncology Group to expand a multicenter phase I/II clinical trial of AZD1775 and the chemotherapy agent irinotecan to include high-risk pediatric rhabdomyosarcoma patients.

"This research offers a template for exploring the origins and vulnerabilities of solid tumors by looking not only at somatic mutations, but also at epigenetic changes and ultimately differences in how those changes are manifest in protein expression and activity," said senior and corresponding author Michael Dyer, Ph.D., chair of the St. Jude Department of Developmental Neurobiology and a Howard Hughes Medical Institute investigator. "The research also highlights how preclinical models and extensive preclinical testing can help prioritize and streamline drug development."

"As genome sequencing technology improves, we continue to learn new information—not just about about the genetic alterations underlying certain cancers but about epigenetic changes and pathways disrupted by cancer," said Robert Fulton, director of technical development at Washington University's McDonnell Genome Institute. "This knowledge is critical for developing more effective drugs and treatment strategies."


The research extensively profiled cell signaling pathways disrupted in rhabdomyosarcoma, including the newly identified G2/M pathway and the unfolded protein response pathway. The analysis also confirmed previous reports that the RAS pathway is deregulated in rhabdomyosarcoma. AZD1775 inhibits an enzyme (WEE1) in the G2/M pathway, which helps regulate cell division, a process that is disrupted in cancer. In contrast, the unfolded protein response pathway is involved in protein folding, which helps maintain cellular homeostasis.

AZD1775's potential for treatment of high-risk rhabdomyosarcoma was identified through extensive preclinical testing, which began with screening more than 1,700 drug-tumor combinations.

The testing ultimately involved tracking the safety and effectiveness of several promising drug candidates in hundreds of mice with different human rhabdomyosarcoma tumors grown in the muscle. These tumors, called orthotopic patient-derived xenografts, provide a more realistic model for preclinical testing of drugs.

Along with the disrupted pathways, researchers discovered that the two main varieties of rhabdomyosarcoma—embryonal and alveolar—occurred at different developmental timepoints. "We knew embryonal and alveolar rhabdomyosarcoma involve different mutations, often occur in different locations in the body and are most common in children of different ages," Stewart said. "Now we have evidence they involve genes active at different stages of development and that alveolar rhabdomyosarcoma occurs further along the developmental program as cells become more specialized."


The study is notable for the breadth and depth of the analysis.

Since its launch in 2010, the Pediatric Cancer Genome Project has sequenced the complete normal and cancer genomes of 700 young cancer patients, including patients with rhabdomyosarcoma.

This study expanded the project to include whole-genome bisulfite sequencing and chromatin immunoprecipitation (ChIP) to study epigenetic differences in tumor and normal tissue. The epigenome includes chemical tags like methyl groups that attach to DNA and histones to switch genes on and off to regulate protein expression.

Researchers used additional methods, including RNA sequencing, to compare gene expression and quantify protein expression (the proteome) and activity (the phosphoproteome.) "The proteomic and phosphoproteomic analysis made it possible to take a closer look at pathways that help explain tumor formation and provide insight into potential vulnerabilities," Stewart said. Wang, one of the first authors, led that effort.


Pediatric solid tumors like rhabdomyosarcoma are rare and so are the tissue samples researchers need to better understand and treat the diseases.

Tumor tissue in this study came from orthotopic patient-derived xenografts. The samples are part of a larger ongoing effort based at St. Jude and led by Dyer and Alberto Pappo, M.D., of the St. Jude Department of Oncology. The goal is to share these orthotopic patient-derived xenografts of and other pediatric solid tumors with researchers around the world to accelerate efforts that could lead to improved outcomes for patients.

The samples and related scientific data are available to researchers worldwide through the Childhood Solid Tumor Network, which is based at St. Jude. The resources come with no obligation to collaborate with St. Jude scientists.

Researchers can also access study data through the online PeCan portal developed by St. Jude.

Explore further: Scientists unveil powerful resource to advance treatment of pediatric solid tumors

Related Stories

Scientists unveil powerful resource to advance treatment of pediatric solid tumors

August 30, 2017
In an effort to improve outcomes for patients with some of the deadliest childhood cancers, St. Jude Children's Research Hospital scientists have created the world's largest collection of pediatric solid tumor samples, drug-sensitivity ...

Gene sequencing project finds family of drugs with promise for treating childhood tumor

December 9, 2013
Drugs that enhance a process called oxidative stress were found to kill rhabdomyosarcoma tumor cells growing in the laboratory and possibly bolstered the effectiveness of chemotherapy against this aggressive tumor of muscle ...

New tools used to identify childhood cancer genes

July 3, 2018
Using a new computational strategy, researchers at UT Southwestern Medical Center have identified 29 genetic changes that can contribute to rhabdomyosarcoma, an aggressive childhood cancer. The group used Bayesian analysis, ...

Researchers discover that a 'muscle' cancer is not really a muscle cancer

January 8, 2018
St. Jude Children's Research Hospital oncologists have discovered the cell type that gives rise to rhabdomyosarcoma, the most prevalent soft tissue cancer in children. Previously, scientists thought the cancer arose from ...

Scientists map gene changes driving tumors in common pediatric soft-tissue cancer

January 23, 2014
(Medical Xpress)—Scientists have mapped the genetic changes that drive tumors in rhabdomyosarcoma, a pediatric soft-tissue cancer, and found that the disease is characterized by two distinct genotypes. The genetic alterations ...

Zebrafish expose tumor pathway in childhood muscle cancer

June 5, 2018
A popular aquarium fish may hold answers to how tumors form in a childhood cancer.

Recommended for you

Potential seen for tailoring treatment for acute myeloid leukemia

December 8, 2018
Advances in rapid screening of leukemia cells for drug susceptibility and resistance are bringing scientists closer to patient-tailored treatment for acute myeloid leukemia (AML).

Study may offer doctors a more effective way to treat neuroblastoma

December 7, 2018
A very large team of researchers, mostly from multiple institutions across Germany, has found what might be a better way to treat patients with neuroblastoma, a type of cancer. In their paper published in the journal Science, ...

Inflammatory bowel disease linked to prostate cancer

December 7, 2018
Men with inflammatory bowel disease have four to five times higher risk of being diagnosed with prostate cancer, reports a 20-year study from Northwestern Medicine.

'Chemo brain' caused by malfunction in three types of brain cells, study finds

December 6, 2018
More than half of cancer survivors suffer from cognitive impairment from chemotherapy that lingers for months or years after the cancer is gone. In a new study explaining the cellular mechanisms behind this condition, scientists ...

Scientists develop new technology for profiling unique genetic makeup of myeloma tumor cells

December 6, 2018
Cancer arises when cells lose control. Deciphering the "blueprint" of cancer cells—outlining how cancer cells hijack specific pathways for uncontrolled proliferation—will lead to more efficient ways to fight it. Joint ...

Putting the brakes on tumor stealth

December 6, 2018
New research undertaken at Monash University has shed new light on how some cancers are able to escape our immune system.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.